Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CBSCNASDAQ:CLGNNASDAQ:GRCEOTCMKTS:SPHRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBSCCardiac Biotech Solutions$0.04-8.3%$0.04$0.02▼$0.15$7.86M1.138,329 shs104,101 shsCLGNCollPlant Biotechnologies$1.35-0.7%$1.93$1.31▼$5.48$17.29M1.3534,588 shs44,698 shsGRCEGrace Therapeutics$2.96-0.3%$2.85$1.75▼$4.97$41.07M0.9253,745 shs16,034 shsSPHRYStarpharma$0.59+2.2%$0.58$0.47▼$0.80$24.02M0.7620 shs2,158 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBSCCardiac Biotech Solutions-8.33%-11.82%-2.22%+21.88%-26.67%CLGNCollPlant Biotechnologies-0.74%-10.00%-56.87%-47.67%-72.89%GRCEGrace Therapeutics-0.34%-1.33%+6.09%+28.14%+295,999,900.00%SPHRYStarpharma+2.21%+2.21%+4.57%-8.28%-6.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBSCCardiac Biotech SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACLGNCollPlant Biotechnologies3.0847 of 5 stars3.75.00.00.02.70.00.6GRCEGrace Therapeutics2.3261 of 5 stars3.50.00.00.01.80.81.3SPHRYStarpharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBSCCardiac Biotech Solutions 0.00N/AN/AN/ACLGNCollPlant Biotechnologies 3.33Buy$11.50751.85% UpsideGRCEGrace Therapeutics 3.00Buy$12.00305.41% UpsideSPHRYStarpharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CBSC, CLGN, SPHRY, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBSCCardiac Biotech Solutions$140K51.44N/AN/AN/A∞CLGNCollPlant Biotechnologies$510K33.67N/AN/A$1.18 per share1.14GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ASPHRYStarpharma$6.40M3.84N/AN/A$0.45 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBSCCardiac Biotech SolutionsN/AN/A0.00∞N/AN/AN/AN/AN/ACLGNCollPlant Biotechnologies-$16.61M-$1.22N/AN/AN/A-560.92%-87.33%-65.31%7/16/2025 (Estimated)GRCEGrace Therapeutics-$9.57M-$1.16N/AN/AN/AN/A-19.45%-16.99%N/ASPHRYStarpharma-$5.36MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Latest CBSC, CLGN, SPHRY, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23-$0.21+$0.02$0.01N/AN/A6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBSCCardiac Biotech SolutionsN/AN/AN/AN/AN/ACLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ASPHRYStarpharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBSCCardiac Biotech SolutionsN/AN/AN/ACLGNCollPlant BiotechnologiesN/A4.484.23GRCEGrace TherapeuticsN/A11.7711.77SPHRYStarpharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBSCCardiac Biotech SolutionsN/ACLGNCollPlant Biotechnologies21.69%GRCEGrace Therapeutics6.08%SPHRYStarpharmaN/AInsider OwnershipCompanyInsider OwnershipCBSCCardiac Biotech SolutionsN/ACLGNCollPlant Biotechnologies9.60%GRCEGrace Therapeutics13.51%SPHRYStarpharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBSCCardiac Biotech Solutions5163.67 millionN/ANot OptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableGRCEGrace TherapeuticsN/A13.83 million11.96 millionN/ASPHRYStarpharma4541.82 millionN/ANot OptionableCBSC, CLGN, SPHRY, and GRCE HeadlinesRecent News About These CompaniesSPHRY Starpharma Holdings LimitedJune 19, 2025 | seekingalpha.comChange in Substantial Holder’s Voting Power at Starpharma HoldingsJune 3, 2025 | tipranks.comPleasing Signs As A Number Of Insiders Buy Starpharma Holdings StockMay 5, 2025 | uk.finance.yahoo.comStarpharma Advances Strategic Initiatives and Expands Market PresenceApril 29, 2025 | tipranks.comIs Starpharma Holdings (ASX:SPL) In A Good Position To Deliver On Growth Plans?March 25, 2025 | finance.yahoo.comRobmar Investments Acquires Substantial Stake in Starpharma HoldingsMarch 17, 2025 | tipranks.comStarpharma Highlights DEP® Dendrimer Platform at PepTalk ConferenceJanuary 15, 2025 | tipranks.comAstodrimer by Starpharma for Coronavirus Disease 2019 (COVID-19): Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPStarpharma CEO Receives Major Performance Rights IssuanceDecember 12, 2024 | markets.businessinsider.comStarpharma Issues Unquoted Securities to Boost Employee IncentivesDecember 12, 2024 | markets.businessinsider.comStarpharma Holdings Reports Successful AGM ResultsNovember 29, 2024 | tipranks.comStarpharma Holdings Schedules Reconvened AGM for Key VoteNovember 26, 2024 | tipranks.comStarpharma AGM Results Highlight Voting ChallengesNovember 26, 2024 | tipranks.comStarpharma Holdings Highlights Strategic Advances in 2024November 25, 2024 | tipranks.comStarpharma Highlights Dendrimer Technology at Healthcare ConferenceNovember 18, 2024 | markets.businessinsider.comStarpharma Showcases Dendrimer Innovations at Microcap ConferenceOctober 29, 2024 | markets.businessinsider.comMedicxi, Starpharma create Petalion with $25M roundApril 9, 2024 | bioworld.comBMedicxi and Starpharma to develop dendrimer-based cancer treatmentsApril 8, 2024 | pharmaceutical-technology.comPStarpharma Holdings Ltd. ADRMarch 14, 2024 | wsj.comNews - StarpharmaFebruary 20, 2024 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBSC, CLGN, SPHRY, and GRCE Company DescriptionsCardiac Biotech Solutions OTCMKTS:CBSC$0.04 0.00 (-8.33%) As of 07/1/2025 03:53 PM EasternCB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.CollPlant Biotechnologies NASDAQ:CLGN$1.35 -0.01 (-0.74%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$1.48 +0.14 (+10.00%) As of 07/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Grace Therapeutics NASDAQ:GRCE$2.96 -0.01 (-0.34%) As of 07/1/2025 04:00 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Starpharma OTCMKTS:SPHRY$0.59 +0.01 (+2.21%) As of 07/1/2025 01:51 PM EasternStarpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
